You are here: Industry Insights > NHS

News List

NHS to launch subscription service to encourage R&D europeanpharmaceuticalreview
July 12, 2019
The NHS is set to launch a new payment method for antibiotic development to incentivise pharmaceutical companies.
NHS releases guidance to remove drugs from prescription list europeanpharmaceuticalreview
July 10, 2019
Seven medications have been suggested for removal from prescriptions by the NHS after a public consultation.
NICE recommends Pfizer’s dacomitinib for NSCLC patients pharmaceutical-technology
July 09, 2019
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Pfizer’s dacomitinib (Vizimpro) as a first-line treatment for non-small-cell lung cancer (NSCLC) patients on the National Health Service (NHS).
Decision by NICE for the use of osimertinib to be appealed europeanpharmaceuticalreview
July 08, 2019
A pharmaceutical company will appeal a decision by NICE to not recommend osimertinib for use within NHS England.
Libtayo approved for CSCC in the EU, including through the NHS in the UK pharmaceutical-technology
July 04, 2019
Sanofi and Regeneron have announced that the European Commission (EC) has granted conditional approval to Libtayo (cemiplimab) for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), a form of skin cancer, who cannot be
Four pharmaceutical companies accused of illegal anti-competitive conduct europeanpharmaceuticalreview
June 21, 2019
The CMA has revealed findings that provisionally show that four pharmaceutical companies have broken the law.
NHS Long Term Plan stunted by lack of workforce investment pharmatimes
June 18, 2019
New research from MHP Communications has found that alleviating workforce pressures is the number one priority for NHS Leaders in England.
BMS’ Opdivo plus Yervoy for RCC to be available through NHS Scotland pharmaceutical-technology
June 13, 2019
Scotland’s healthcare pricing regulator the Scottish Medicines Consortium (SMC) has decided to fund Bristol-Myers Squibb (BMS)’s Opdivo (nivolumab) plus Yervoy (ipilimumab) for use in NHS Scotland for renal cell carcinoma (RCC) patients ...
New NHS innovations to benefit 750,000 pharmatimes
June 11, 2019
NHS England has announced that nearly three quarters of a million patients are set to benefit from new world-leading innovations on the service.
NICE recommends Prevymis on the NHS after re-evaluation europeanpharmaceuticalreview
June 05, 2019
The National Institute for Health and Care Excellence is recommending MSD’s Prevymis (letermovir) within the NHS.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 44 45 Next page